SeraGene Therapeutics is a pre-clinical stage company using RNA and nanomedicine technology to provide long lasting, targeted control for coagulation disorders. Leveraging a deep understanding of clotting biology and prophylaxis, SeraGene is developing a portfolio of first-in-class therapies targeting proteins implicated in dozens of diseases across thrombosis, inflammation, and bleeding. Our two lead assets are first-in-class therapies for the bleeding disorder Von Willebrand disease (VWD, SG-100), and Cancer-associated Thrombosis (SG-200). These assets uniquely target disordered coagulation to afford a treatment that has the potential to deliver unprecedented efficacy and safety features. With $670k USD of pre-seed investment, SG-100 and SG-200 has advanced to the late stages of lead optimization, with validated efficacy in large animal disease models. Future seed funding will be used for IND-enabling studies as well as key hires in product and business development.